Sana Biotechnology (SANA) Asset Writedowns and Impairment (2024)

Sana Biotechnology's (SANA) quarterly Asset Writedowns and Impairment came in at $1.9 million in Q4 2024.

Sana Biotechnology (SANA) Asset Writedowns and Impairment (2024) Analysis & Trends

Sana Biotechnology has disclosed Asset Writedowns and Impairment across 1 years of filings, most recently posting $1.9 million for Q4 2024.

Asset Writedowns and Impairment for Q4 2024 came in at $1.9 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $1.9 million (changed N/A YoY), and the FY2025 annual result was $44.6 million, up 2259.12% from the prior year.
Asset Writedowns and Impairment came in at $1.9 million for Q4 2024 at Sana Biotechnology.
In the past five years, Asset Writedowns and Impairment ranged from a high of $1.9 million in Q4 2024 to a low of $1.9 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn
9	Abivax	90.15 Bn	90.15 Bn	-
10	Sana Biotechnology	746.13 Mn	746.13 Mn	-

Download Data

Date	Value
Dec 31, 2024	1.89 Mn
Dec 31, 2024	1.89 Mn